Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2025-08-20 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '半年度报告' which translates to 'Half-Year Report' or 'Interim Report' for the period 2025. It contains detailed financial data including income, profit, assets, liabilities, and operational details for the six months ending June 30, 2025. The content includes sections on accounting data, business overview, risk factors, financial analysis, and operational review. It explicitly states the report period as January 1, 2025 to June 30, 2025. The document is comprehensive and contains actual financial statements and substantive financial analysis, not just an announcement or summary. It is not an earnings release or a regulatory filing announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-20 Chinese
关于注销分公司的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the cancellation (注销) of two branch offices. It includes details about the branches, the board meeting resolution approving the cancellation, and the impact on the company. There is no financial data, no mention of annual or quarterly reports, no audit information, no earnings data, no voting results, no legal proceedings, no capital changes, and no merger or acquisition activity. The document is a formal corporate announcement about management decisions related to branch closures, approved by the board, and does not fit into financial report categories. It is not a report publication announcement because it contains substantive content about the cancellation decision itself. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-08-20 Chinese
2025年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and actual use of funds raised by Beijing Kangle Weishi Biotechnology Co., Ltd. during the half-year period of 2025. It includes specifics on fundraising amounts, dates, usage, changes in fund usage, and compliance with regulatory requirements. The document references approvals from the China Securities Regulatory Commission, detailed tables of fund usage, changes in investment projects, and confirmations of no misuse of funds. The content is focused on the management and use of capital raised through stock issuance, including detailed financial figures and regulatory compliance. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an announcement of a report but a substantive report itself, with actual financial data and analysis related to fundraising and capital use.
2025-08-20 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '半年度报告摘要' which translates to 'Half-Year Report Summary' or 'Interim Report Summary'. It contains detailed financial data for the half-year period ending June 30, 2025, including assets, liabilities, net profit, earnings per share, and shareholder information. The document also discusses business operations, changes in shareholding, and other important matters relevant to the interim period. The length of the document (6441 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-20 Chinese
第五届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 11th meeting of the 5th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting's attendance, the approval of the 2025 semi-annual report and its summary, a special report on the use of raised funds, and the decision to cancel certain branch offices. The document references that the actual reports are disclosed separately on the Beijing Stock Exchange information disclosure platform. The document itself does not contain the full semi-annual report or detailed financial data but is an announcement of board meeting decisions and approvals. This fits the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions rather than providing the full financial report or detailed data.
2025-08-20 Chinese
关于全资子公司增资扩股的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a capital increase and equity expansion in a wholly-owned subsidiary of the company. It details the transaction overview, changes in shareholding structure, and completion of registration procedures. The document does not contain financial statements or detailed financial analysis but rather informs about a financing event and related corporate actions. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is short and focused on the transaction progress, not a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2025-08-20 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.